Recent observation of the efficacy and safety on Rivaroxaban in patients presenting with STEMI

摘要：

Background ATLAS ACS 2 TIMI 51 has authenticated that, compared with placebo, Rivaroxaban has an outstanding superiority on patients presenting with STEMI in lessening mortality of cardiovascular events.We assessed whether it is beneficial or safe for Chinese through the clinical observation.

作者: ZHANG Ming ZHANG Wen-wen

作者单位: Liaoning Jinqiu Hospital Third Affiliated Hospital of L UTCM

会议类型: 国内会议

会议名称: 第11届中国介入心脏病学大会

会议地点: 北京

会议语种:英文

页码: 277-277

在线出版日期: 2013-03-20（万方平台首次上网日期，不代表论文的发表时间）